GlassScriptPhysician profile
Stephen V Savran
NPI 1982610267
$658.07
in general payments reported to CMS, 2019-2025
12 companies · $66.35 in 2025
The $66.35 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2022: $232 · 2024: $17.26 · 2025: $66.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acist Medical Systems, INC. | $170.50 | 2019-2022 | |
| Boston Scientific Corporation | $127.50 | 2019-2024 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $111.94 | 2019 | |
| Cleerly, INC. | $49.56 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Impulse Dynamics (USA) INC. | $43.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $40.48 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.60 | 2019 | |
| Pfizer INC. | $24.22 | 2022 | |
| Angiodynamics, INC. | $19.52 | 2019 | |
| Abbott Laboratories | $16.79 | 2025 | 2nd Gen Centrimag Primary Console |
| Sanofi-Aventis U.S. LLC | $14.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Savran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.